Cognition TherapeuticsCGTX
CGTX
About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Employees: 25
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.71% less ownership
Funds ownership: 18.76% [Q1] → 18.05% (-0.71%) [Q2]
6% less funds holding
Funds holding: 51 [Q1] → 48 (-3) [Q2]
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
28% less capital invested
Capital invested by funds: $4.89M [Q1] → $3.5M (-$1.39M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
5%
upside
Avg. target
$3.50
23%
upside
High target
$4
40%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin | 40%upside $4 | Buy Maintained | 8 Aug 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 5%upside $3 | Buy Reiterated | 26 Jun 2025 |
Financial journalist opinion
Based on 5 articles about CGTX published over the past 30 days
Neutral
GlobeNewsWire
9 hours ago
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has regained compliance with the exchange's continued listing standard for minimum share price under Rule 5550(a)(2) (the “Bid Price Rule”).
Positive
Seeking Alpha
15 hours ago
Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating
I rate Cognition Therapeutics a "Strong Buy" due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low p-tau217; Successful results means NDA filing. Zervimesine showed a remarkable 95% slowing of cognitive decline in the low-ptau217 biomarker-defined subgroup, supporting a precision medicine approach and strong phase 3 prospects. The company is well-financed through government grants and has multiple funding options, with operational funding into Q2 2026, reducing near-term dilution risk.
Neutral
GlobeNewsWire
2 weeks ago
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease
- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, received final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the end-of-Phase 2 meeting that was conducted on July 9, 2025.
Neutral
The Motley Fool
2 weeks ago
Cognition (CGTX) Q2 Grant Income Jumps
Cognition Therapeutics (CGTX -4.78%), a clinical-stage biotechnology firm focused on developing therapies for neurodegenerative diseases, released its earnings for Q2 2025 on August 7, 2025. The company reported a GAAP net loss per share of $(0.11) for Q2 2025, missing consensus estimates by $(0.005)
Neutral
GlobeNewsWire
4 weeks ago
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease
- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment - - Plasma and CSF biomarkers support zervimesine's impact on Alzheimer's disease biology -
Neutral
GlobeNewsWire
1 month ago
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study
Neutral
GlobeNewsWire
1 month ago
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo -
Neutral
GlobeNewsWire
1 month ago
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease
PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025.
Neutral
GlobeNewsWire
1 month ago
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target
PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START' Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer's Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
Neutral
GlobeNewsWire
2 months ago
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025.
Charts implemented using Lightweight Charts™